Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
paliperidone; Carbamazepine · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| paliperidone ER; Carbamazepine | DRUG | - |
Inclusion Criteria: * Diagnosis of schizophrenia of any subtype (295.10 * 295.20 * 295.30 * 295.60 * 295.90) or bipolar I disorder (296.0x, 296.4x, 296.5x, 296.6x or 296.7), according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) * Clinically stable with no p...
Paliperidone and carbamazepine are being studied for use in schizophrenia. The combination is being investigated in a clinical trial that also includes patients with bipolar I disorder. Paliperidone is an extended release formulation, and carbamazepine is being evaluated for its effect on paliperidone's pharmacokinetics.
Johnson & Johnson (NYSE: JNJ) is developing paliperidone and carbamazepine. The company is conducting a Phase 1 clinical trial to study the effect of carbamazepine on the pharmacokinetics of paliperidone extended release in patients with schizophrenia or bipolar I disorder.
Paliperidone and carbamazepine are in Phase 1 clinical development. The combination is investigational and has not been approved by the FDA. One Phase 1 trial has been completed, with no active trials currently ongoing.
Paliperidone and carbamazepine have one completed clinical trial, NCT00892125. This Phase 1 study evaluated the effect of carbamazepine on the pharmacokinetics of paliperidone extended release in patients with schizophrenia or bipolar I disorder. The trial enrolled 64 participants and was uncontrolled.
Paliperidone is an atypical antipsychotic that works by blocking dopamine and serotonin receptors in the brain. Carbamazepine is an anticonvulsant that may affect the metabolism of paliperidone. The combination is being studied to understand how carbamazepine influences paliperidone levels in the body.